A Prospective Clinical Study to Validate a Preoperative Risk Scoring Model for LNM in GC Patients

The study was a single-centre, prospective study. Data prospectively accrued were employed to evaluate the concordance between observed patient outcomes, with respect to lymph node metastasis status post-curative gastrectomy, and the prognostications tendered by the established risk scoring model, thereby appraising the model's clinical applicability and validity.

Inclusion criteria

• Primary gastric adenocarcinoma;
• Curative surgery (with R0 resection, excluding palliative surgery and cases with distant metastasis).

Exclusion criteria

• Patients with autoimmune diseases, inflammation, or hematological disorders;
• Patients with a history of or concurrent other cancers;
• Presence of active infection and inflammation (based on WBC count, patients with count of 10×10^9 or higher should be evaluated through medical record examination for the presence of infection);
• Active bleeding (as determined by endoscopic ultrasound and HGB ≤ 90);
• Post neoadjuvant radiotherapy or chemotherapy;
• History of blood transfusion, corticosteroid use, or leukocyte-stimulating medications within the past month prior to blood draw;
• Incomplete clinical and pathological data.